NeoGenomics Quarterly Income Statements Chart
Quarterly
|
Annual
NeoGenomics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-09-30 | 2008-12-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| net revenue | 181,330,000 | 168,035,000 | 27,279,000 | 25,126,000 | 24,370,000 | 23,026,000 | 24,999,000 | 23,217,000 | 20,670,000 | 18,182,000 | 18,323,000 | 16,884,000 | 15,603,000 | 15,657,000 | 14,894,000 | 14,202,000 | 15,611,000 | 15,160,000 | 12,893,000 | 11,320,000 | 10,466,000 | 8,805,000 | 8,755,000 | 8,708,000 | 8,490,000 | 8,418,000 | 7,296,800 | 14,094,959 | 4,881,402 | 4,162,762 | |||||||||||||||||||||||||||||||||||||
| cost of revenue | 104,072,000 | 94,789,000 | 94,743,000 | 92,944,000 | 92,008,000 | 90,771,000 | 87,964,000 | 89,643,000 | 87,026,000 | 82,406,000 | 81,880,000 | 79,889,000 | 81,126,000 | 78,937,000 | 80,475,000 | 74,101,000 | 68,734,000 | 73,959,000 | 68,544,000 | 71,379,000 | 58,971,000 | 59,661,000 | 56,945,000 | 53,840,000 | 52,747,000 | 48,462,000 | 39,365,000 | 36,775,000 | 37,216,000 | 36,120,000 | 34,661,000 | 34,242,000 | 34,912,000 | 34,480,000 | 33,233,000 | 33,416,000 | 34,524,000 | 32,531,000 | 15,051,000 | 13,955,000 | 13,557,000 | 13,482,000 | 13,529,000 | 12,923,000 | 10,431,000 | 9,473,000 | 9,160,000 | 8,713,000 | 8,446,000 | 8,411,000 | 8,460,000 | 8,310,000 | 8,244,000 | 8,016,000 | 7,060,000 | 6,246,000 | 5,810,000 | 4,940,000 | 4,851,000 | 4,818,000 | 4,575,000 | 4,344,000 | 3,672,289 | 6,577,549 | 2,183,758 | 1,858,474 | |
| gross profit | 77,258,000 | 73,246,000 | 77,257,000 | 74,880,000 | 72,494,000 | 65,469,000 | 67,588,000 | 62,311,000 | 59,891,000 | 54,814,000 | 56,825,000 | 48,893,000 | 43,946,000 | 38,232,000 | 45,257,000 | 47,239,000 | 52,990,000 | 41,574,000 | 57,453,000 | 54,065,000 | 28,006,000 | 46,369,000 | 49,923,000 | 50,832,000 | 48,966,000 | 47,115,000 | 22,538,750 | 32,321,000 | 30,530,000 | 27,303,000 | 21,796,000 | 28,810,000 | 31,178,000 | 7,311,000 | 10,294,000 | 10,239,000 | 5,643,500 | 8,171,000 | 7,157,000 | 5,100,500 | 5,892,000 | 7,367,000 | 3,398,750 | 5,074,000 | 4,656,000 | 2,969,750 | 3,890,000 | 3,915,000 | 3,624,511 | 7,517,410 | 2,697,644 | 2,304,288 | |||||||||||||||
| yoy | 6.57% | 11.88% | 14.31% | 20.17% | 21.04% | 19.44% | 18.94% | 27.44% | 36.28% | 43.37% | 25.56% | 3.50% | -17.07% | -8.04% | -21.23% | -12.63% | 89.21% | -10.34% | 15.08% | 6.36% | -42.81% | -1.58% | 121.50% | 57.27% | 60.39% | 72.56% | 3.41% | 12.19% | -2.08% | 29.55% | 25.98% | 43.06% | 10.65% | 38.68% | -2.85% | 50.07% | 16.12% | 58.23% | 14.45% | 30.44% | 18.93% | -18.06% | -47.92% | 57.29% | |||||||||||||||||||||||
| qoq | 5.48% | -5.19% | 3.17% | 3.29% | 10.73% | -3.14% | 8.47% | 4.04% | 9.26% | -3.54% | 16.22% | 11.26% | 14.95% | -15.52% | -4.20% | -10.85% | 27.46% | -27.64% | 6.27% | 93.05% | -39.60% | -7.12% | -1.79% | 3.81% | 3.93% | 109.04% | -30.27% | 5.87% | 11.82% | 25.27% | -24.35% | -7.60% | -28.98% | 0.54% | -30.93% | 14.17% | -13.43% | -20.02% | -33.02% | 8.98% | -23.66% | -0.64% | 178.67% | 17.07% | |||||||||||||||||||||||
| gross margin % | 63.25% | 44.62% | 44.07% | 41.90% | 43.45% | 41.01% | 40.77% | 39.95% | 40.97% | 37.97% | 35.14% | 32.63% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| general and administrative | 71,747,000 | 68,207,000 | 63,643,000 | 66,969,000 | 63,328,000 | 65,797,000 | 59,758,000 | 61,486,000 | 60,308,000 | 61,549,000 | 54,875,000 | 64,282,000 | 57,951,000 | 66,248,000 | 62,394,000 | 63,839,000 | 54,638,000 | 40,476,000 | 36,709,000 | 36,128,000 | 34,613,000 | 36,344,000 | 33,220,000 | 33,054,000 | 29,577,000 | 32,142,000 | 25,716,000 | 21,055,000 | 20,983,000 | 17,067,000 | 22,012,000 | 23,267,000 | 22,675,000 | 20,801,000 | 19,972,000 | 19,025,000 | 18,779,000 | 18,005,000 | 12,595,000 | 7,438,000 | 7,075,000 | 6,522,000 | 6,513,000 | 6,370,000 | 5,870,000 | 5,054,000 | 4,824,000 | 4,335,000 | 4,064,000 | 4,175,000 | 4,098,000 | 3,929,000 | 4,066,000 | 3,750,000 | 3,657,000 | 3,307,000 | 3,086,000 | 2,823,000 | 2,677,000 | 2,919,000 | 2,769,000 | 2,902,000 | 2,457,978 | 7,706,284 | 2,556,121 | 2,514,555 | |
| research and development | 9,023,000 | 10,181,000 | 7,969,000 | 7,684,000 | 7,886,000 | 7,620,000 | 7,127,000 | 5,285,000 | 7,502,000 | 7,395,000 | 6,675,000 | 7,312,000 | 8,626,000 | 7,713,000 | 8,513,000 | 7,409,000 | 3,495,000 | 2,456,000 | 2,100,000 | 1,964,000 | 2,105,000 | 2,060,000 | 2,080,000 | 2,611,000 | 2,587,000 | 1,209,000 | 526,000 | 446,000 | 1,073,000 | 956,000 | 556,000 | 1,270,000 | 947,000 | 862,000 | 930,000 | 967,000 | 1,306,000 | 1,446,000 | 1,856,000 | 871,000 | 803,000 | 669,000 | 414,000 | 1,014,000 | 633,000 | 628,000 | 649,000 | 340,000 | 616,000 | 835,000 | 448,000 | 808,000 | 528,000 | 497,000 | |||||||||||||
| sales and marketing | 24,075,000 | 22,683,000 | 22,339,000 | 20,415,000 | 21,677,000 | 20,221,000 | 18,072,000 | 17,610,000 | 18,901,000 | 16,259,000 | 17,142,000 | 16,809,000 | 17,071,000 | 16,299,000 | 15,917,000 | 15,704,000 | 17,224,000 | 13,749,000 | 13,105,000 | 11,304,000 | 10,195,000 | 13,258,000 | 12,302,000 | 11,508,000 | 12,324,000 | 11,216,000 | 8,047,000 | 6,900,000 | 7,680,000 | 6,775,000 | 6,077,000 | 6,577,000 | 6,242,000 | 5,648,000 | 5,826,000 | 5,958,000 | 6,327,000 | 5,800,000 | 2,993,000 | 2,748,000 | 2,907,000 | 2,914,000 | 3,224,000 | 2,983,000 | 3,158,000 | 2,633,000 | 2,487,000 | 2,336,000 | 1,972,000 | 1,931,000 | 1,692,000 | 1,839,000 | 1,934,000 | 2,036,000 | 1,801,000 | 1,725,000 | 1,684,000 | 1,753,000 | 1,790,000 | 1,983,000 | 1,943,000 | 1,763,000 | 1,792,955 | ||||
| restructuring charges | 1,707,000 | 1,009,000 | 1,544,000 | 2,398,000 | 1,205,000 | 2,125,000 | 3,074,000 | 4,684,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| impairment charges | 20,041,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total operating expenses | 124,886,000 | 101,071,000 | 95,658,000 | 96,077,000 | 94,435,000 | 96,036,000 | 86,162,000 | 86,506,000 | 89,785,000 | 89,887,000 | 83,208,000 | 88,403,000 | 83,648,000 | 90,260,000 | 86,824,000 | 86,952,000 | 75,357,000 | 56,681,000 | 51,914,000 | 49,396,000 | 46,913,000 | 51,662,000 | 47,602,000 | 47,173,000 | 44,488,000 | 44,567,000 | 34,289,000 | 28,401,000 | 29,736,000 | 24,798,000 | 28,645,000 | 32,172,000 | 29,864,000 | 27,311,000 | 30,192,000 | 25,950,000 | 26,412,000 | 25,251,000 | 17,444,000 | 11,057,000 | 10,785,000 | 10,105,000 | 10,151,000 | 10,367,000 | 9,661,000 | 8,315,000 | 7,960,000 | 7,011,000 | 6,652,000 | 6,941,000 | 6,238,000 | 6,576,000 | 6,528,000 | 6,283,000 | 3,594,750 | 5,032,000 | 4,770,000 | 4,576,000 | 3,569,750 | 4,902,000 | 4,712,000 | 4,665,000 | 4,379,816 | 7,905,620 | 2,625,367 | 2,569,651 | |
| income from operations | -47,628,000 | -27,825,000 | -18,401,000 | -21,197,000 | -21,941,000 | -30,567,000 | -18,574,000 | -24,195,000 | -29,894,000 | -35,073,000 | -26,383,000 | -39,510,000 | -39,702,000 | -52,028,000 | -41,567,000 | -39,713,000 | -22,367,000 | -15,107,000 | 5,539,000 | 4,669,000 | -18,907,000 | -5,293,000 | 2,321,000 | 3,659,000 | 4,478,000 | 2,548,000 | 2,821,000 | 3,920,000 | 794,000 | 2,505,000 | 4,487,000 | -3,362,000 | 1,314,000 | -115,000 | -2,935,000 | 1,395,000 | 2,193,000 | 1,922,000 | -5,216,000 | 114,000 | 28,000 | -561,000 | 1,319,000 | -73,000 | 578,000 | 394,000 | 1,203,000 | 1,160,000 | 505,000 | 305,000 | 196,000 | -684,000 | 839,000 | 375,000 | 42,000 | -114,000 | -563,000 | -1,012,000 | -797,000 | ||||||||
| yoy | 117.07% | -8.97% | -0.93% | -12.39% | -26.60% | -12.85% | -29.60% | -38.76% | -24.70% | -32.59% | -36.53% | -0.51% | 77.50% | 244.40% | -850.44% | -950.57% | 18.30% | 185.41% | 138.65% | 27.60% | -522.22% | -307.73% | -17.72% | -6.66% | 463.98% | 1.72% | -37.13% | -216.60% | -39.57% | -2278.26% | -252.88% | -341.00% | -40.08% | -105.98% | -43.73% | 1123.68% | 7732.14% | -442.60% | -495.45% | -256.16% | -95.16% | -242.39% | 9.64% | -106.29% | 14.46% | 29.18% | 513.78% | -269.59% | -39.81% | -47.73% | -1728.57% | -835.96% | -166.61% | -104.15% | -85.70% | ||||||||||||
| qoq | 71.17% | 51.21% | -13.19% | -3.39% | -28.22% | 64.57% | -23.23% | -19.06% | -14.77% | 32.94% | -33.22% | -0.48% | -23.69% | 25.17% | 4.67% | 77.55% | 48.06% | -372.74% | 18.63% | -124.69% | 257.21% | -328.05% | -36.57% | -18.29% | 75.75% | -9.68% | -28.04% | 393.70% | -68.30% | -44.17% | -233.46% | -355.86% | -1242.61% | -96.08% | -310.39% | -36.39% | 14.10% | -136.85% | -4675.44% | 307.14% | -104.99% | -142.53% | -1906.85% | -112.63% | 46.70% | -67.25% | 3.71% | 129.70% | 65.57% | 55.61% | -128.65% | -181.53% | 792.86% | -136.84% | -44.37% | 26.98% | |||||||||||
| operating margin % | -15.07% | -12.63% | -13.34% | -19.56% | -11.94% | -15.92% | -20.35% | -25.56% | -19.02% | -30.68% | -31.74% | -44.40% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest income | -2,263,000 | -3,721,000 | -4,328,000 | -4,673,000 | -4,592,000 | -4,834,000 | -10,071,000 | -2,840,000 | -2,524,000 | -1,467,000 | 1,301,000 | 128,883 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest expense | 933,000 | 1,618,000 | 1,624,000 | 1,642,000 | 1,666,000 | 1,685,000 | -860,000 | 139,000 | 926,000 | 1,707,000 | 1,296,000 | 902,000 | 1,177,000 | 2,194,000 | 2,458,000 | 1,548,000 | 819,000 | 380,000 | 203,000 | 1,304,000 | 1,826,000 | 1,191,500 | 1,873,000 | 1,407,000 | 1,486,000 | 1,043,250 | 1,398,000 | 1,411,000 | 1,364,000 | 1,127,250 | 1,468,000 | 1,448,000 | 1,593,000 | 199,336 | 69,246 | 55,096 | |||||||||||||||||||||||||||||||
| other income | -482,000 | -65,000 | 431,000 | -317,000 | 2,000 | 263,000 | -124,000 | 96,000 | -730,000 | 114,000 | 1,000 | -25,000 | 405,000 | 930,000 | -89,000 | -171,000 | 4,854,000 | -4,222,000 | -11,000 | -7,405,000 | -223,000 | -494,000 | -35,000 | -10,000 | 5,169,000 | -45,000 | -30,000 | 124,000 | -63,000 | ||||||||||||||||||||||||||||||||||||||
| income before taxes | -45,816,000 | -25,657,000 | -16,128,000 | -17,849,000 | -19,017,000 | -27,681,000 | -15,286,000 | -21,451,000 | -26,640,000 | -33,720,000 | -25,524,000 | -39,624,000 | -41,033,000 | -53,161,000 | -44,204,000 | -23,170,000 | 73,436,000 | -21,138,000 | 7,567,000 | 2,222,000 | -17,956,000 | -5,889,000 | 2,435,000 | 3,491,000 | 2,166,000 | -4,447,000 | 1,402,000 | 2,077,000 | -737,000 | 1,082,000 | -1,584,000 | -4,760,000 | -97,000 | -1,479,000 | -8,424,000 | -73,000 | 745,000 | 329,000 | 1,126,000 | -291,000 | 325,000 | 963,000 | 929,000 | 273,000 | |||||||||||||||||||||||
| income tax benefit | -724,000 | 266,000 | -804,000 | -150,000 | -375,000 | -620,000 | -960,000 | -2,935,000 | -2,309,000 | -2,925,000 | -2,837,000 | -2,772,000 | -5,730,000 | -2,445,000 | -2,822,000 | -2,437,000 | 1,089,000 | -3,861,000 | 1,348,000 | 175,000 | 1,049,000 | 54,000 | -357,000 | 125,000 | -6,000 | ||||||||||||||||||||||||||||||||||||||||||
| net income | -45,092,000 | -25,923,000 | -15,324,000 | -17,699,000 | -18,642,000 | -27,061,000 | -14,326,000 | -18,516,000 | -24,331,000 | -30,795,000 | -22,687,000 | -36,852,000 | -35,303,000 | -49,408,000 | -41,759,000 | -20,348,000 | 75,873,000 | -22,114,000 | 15,417,000 | 2,557,000 | -6,824,000 | -6,978,000 | 6,296,000 | 2,143,000 | 1,991,000 | -2,424,000 | 353,000 | 2,023,000 | -380,000 | 644,000 | -1,449,250 | -5,100,000 | -43,000 | -654,000 | -6,223,000 | -67,000 | 413,000 | 155,000 | -1,473,000 | -125,000 | -176,000 | -761,000 | 1,047,000 | -291,000 | 274,000 | 102,000 | 857,000 | 900,000 | 273,000 | 3,000 | -113,000 | -975,000 | 551,000 | 603,000 | 152,000 | -143,000 | -293,000 | -893,000 | -377,000 | -1,198,000 | -978,000 | -750,000 | -755,305 | -388,210 | 72,277 | -265,363 | |
| yoy | 141.88% | -4.21% | 6.97% | -4.41% | -23.38% | -12.13% | -36.85% | -49.76% | -31.08% | -37.67% | -45.67% | 81.11% | -146.53% | 123.42% | -370.86% | -895.78% | -1211.86% | 216.91% | 144.87% | 19.32% | -442.74% | 187.87% | 1683.57% | 5.93% | -623.95% | -476.40% | -124.36% | -139.67% | 783.72% | -198.47% | -76.71% | 7511.94% | -110.41% | -521.94% | 322.47% | -46.40% | -334.66% | -120.37% | -240.69% | -57.04% | -164.23% | -846.08% | 22.17% | -132.33% | 0.37% | 3300.00% | -858.41% | -192.31% | -50.45% | -99.50% | -174.34% | 581.82% | -288.05% | -167.53% | -140.32% | -88.06% | -70.04% | 19.07% | -50.09% | 151.93% | -1137.67% | 184.63% | |||||
| qoq | 73.95% | 69.17% | -13.42% | -5.06% | -31.11% | 88.89% | -22.63% | -23.90% | -20.99% | 35.74% | -38.44% | 4.39% | -28.55% | 18.32% | 105.22% | -126.82% | -443.10% | -243.44% | 502.93% | -137.47% | -2.21% | -210.83% | 193.79% | 7.63% | -182.14% | -786.69% | -82.55% | -632.37% | -159.01% | -144.44% | -71.58% | 11760.47% | -93.43% | -89.49% | 9188.06% | -116.22% | 166.45% | -110.52% | 1078.40% | -28.98% | -76.87% | -172.68% | -459.79% | -206.20% | 168.63% | -88.10% | -4.78% | 229.67% | 9000.00% | -102.65% | -88.41% | -276.95% | -8.62% | 296.71% | -206.29% | -51.19% | -67.19% | 136.87% | -68.53% | 22.49% | 30.40% | -0.70% | -637.11% | -127.24% | |||
| net income margin % | -12.55% | -10.55% | -11.33% | -17.32% | -9.21% | -12.19% | -16.56% | -22.44% | -16.36% | -28.62% | -28.23% | -42.17% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per share | -0.005 | 0 | 0 | -0.01 | -0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | -0.35 | -0.2 | -0.12 | -0.14 | -0.15 | -0.21 | -0.11 | -0.15 | -0.19 | -0.25 | -0.18 | -0.3 | -0.28 | -0.4 | -0.35 | -0.17 | 0.64 | -0.19 | 0.14 | 0.02 | -0.06 | -0.07 | -0.03 | -0.043 | -0.1 | -0.03 | -0.04 | -0.053 | -0.07 | -0.07 | -0.07 | ||||||||||||||||||||||||||||||||||||
| diluted | -0.35 | -0.2 | -0.12 | -0.14 | -0.15 | -0.21 | -0.11 | -0.15 | -0.19 | -0.25 | -0.18 | -0.3 | -0.28 | -0.4 | -0.35 | -0.17 | 0.59 | -0.19 | 0.14 | 0.04 | -0.06 | -0.07 | -0.03 | -0.043 | -0.1 | -0.03 | -0.04 | -0.053 | -0.07 | -0.07 | -0.07 | ||||||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | 127,949 | 127,376 | 126,658 | 126,953 | 126,405 | 126,111 | 125,502 | 125,687 | 125,356 | 125,026 | 124,217 | 124,425 | 124,068 | 123,630 | 119,962 | 122,559 | 118,287 | 116,199 | 108,579 | 110,461 | 107,887 | 104,484 | 100,470 | 103,899 | 98,297 | 94,740 | 85,618 | 87,253 | 81,017 | 80,507 | 79,426 | 79,617 | 79,413 | 78,650 | 77,542 | 78,145 | 77,448 | 76,068 | 60,526 | ||||||||||||||||||||||||||||
| diluted | 127,949 | 127,376 | 126,658 | 126,953 | 126,405 | 126,111 | 125,502 | 125,687 | 125,356 | 125,026 | 124,217 | 124,425 | 124,068 | 123,630 | 119,962 | 122,559 | 131,237 | 116,199 | 111,794 | 119,191 | 107,887 | 104,484 | 103,615 | 107,880 | 102,336 | 94,740 | 91,568 | 90,899 | 90,168 | 80,507 | 79,426 | 79,617 | 79,413 | 78,650 | 77,542 | 78,145 | 77,448 | 76,068 | 60,526 | ||||||||||||||||||||||||||||
| clinical services | 105,426,500 | 145,783,000 | 141,388,000 | 134,535,000 | 130,058,000 | 127,553,000 | 123,156,000 | 114,869,000 | 108,166,000 | 106,162,000 | 105,635,000 | 98,791,000 | 104,053,000 | 102,227,000 | 101,405,000 | 96,487,000 | 106,738,000 | 108,733,000 | 73,884,000 | 92,982,000 | 93,404,000 | 92,565,000 | 88,982,000 | 86,210,000 | 65,913,000 | 59,449,000 | 59,540,000 | ||||||||||||||||||||||||||||||||||||||||
| advanced diagnostics | 16,715,000 | 22,041,000 | 23,114,000 | 21,705,000 | 25,494,000 | 24,401,000 | 23,761,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total net revenue | 122,141,500 | 167,824,000 | 164,502,000 | 156,240,000 | 155,552,000 | 151,954,000 | 146,917,000 | 137,220,000 | 138,705,000 | 128,782,000 | 125,072,000 | 117,169,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| yoy | -21.48% | 10.44% | 11.97% | 13.86% | 12.15% | 17.99% | 17.47% | 17.11% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| qoq | -27.22% | 2.02% | 5.29% | 0.44% | 2.37% | 3.43% | 7.07% | -1.07% | 7.71% | 2.97% | 6.74% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| pharma services | 22,351,000 | 30,539,000 | 22,620,000 | 19,437,000 | 18,378,000 | 21,679,000 | 19,113,000 | 20,319,000 | 19,046,000 | 19,259,000 | 16,711,000 | 13,093,000 | 13,048,000 | 13,464,000 | 12,107,000 | 12,731,000 | 9,367,000 | 10,562,000 | 9,647,000 | 8,206,000 | 6,452,000 | 8,713,000 | 6,866,000 | 6,299,000 | 4,986,000 | ||||||||||||||||||||||||||||||||||||||||||
| gain on investment in and loan receivable from non-consolidated affiliate | -17,750,000 | -96,534,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| adjustment to net income for convertible notes in diluted eps | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| convertible note accretion, amortization, and interest, net of tax | 1,552,000 | 1,975,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income used in diluted eps | -35,303,000 | 8,353,000 | -20,348,000 | 77,425,000 | -2,811,250 | 4,532,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other incomes | -168,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax (benefit) expense | -3,753,000 | -7,850,000 | -335,000 | -11,132,000 | -2,023,000 | 438,000 | -134,750 | 340,000 | -54,000 | -825,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net revenue: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total revenue | 89,649,250 | 121,340,000 | 121,724,000 | 115,533,000 | 79,612,750 | 125,444,000 | 86,977,000 | 106,030,000 | 106,868,000 | 104,672,000 | 101,713,000 | 95,577,000 | 76,475,000 | 69,096,000 | 67,746,000 | 63,423,000 | 67,793,000 | 63,052,000 | 66,090,000 | 61,676,000 | 60,490,000 | 60,761,000 | 63,129,000 | 59,704,000 | |||||||||||||||||||||||||||||||||||||||||||
| loss on extinguishment of debt | 1,400,000 | 1,018,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on termination of cash flow hedge | 3,506,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax expense | 976,000 | 332,000 | 174,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| adjustment to the numerator for convertible notes in diluted eps | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| deemed dividends on preferred stock and amortization of beneficial conversion feature | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on redemption of preferred stock | -9,075,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders | 6,296,000 | 2,143,000 | 1,991,000 | -2,424,000 | 353,000 | 2,023,000 | 5,924,000 | -2,212,000 | 2,260,000 | -7,751,000 | -2,682,000 | -3,220,000 | -14,197,000 | -5,634,000 | -5,154,000 | -5,412,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| income per share attributable to common stockholders | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | 0.06 | 0.02 | 0.02 | -0.03 | 0.018 | 0.02 | 0.07 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted | 0.06 | 0.02 | 0.02 | -0.03 | 0.015 | 0.02 | 0.07 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | 127,949 | 127,376 | 126,658 | 126,953 | 126,405 | 126,111 | 125,502 | 125,687 | 125,356 | 125,026 | 124,217 | 124,425 | 124,068 | 123,630 | 119,962 | 122,559 | 118,287 | 116,199 | 108,579 | 110,461 | 107,887 | 104,484 | 100,470 | 103,899 | 98,297 | 94,740 | 85,618 | 87,253 | 81,017 | 80,507 | 79,426 | 79,617 | 79,413 | 78,650 | 77,542 | 78,145 | 77,448 | 76,068 | 60,526 | ||||||||||||||||||||||||||||
| diluted | 127,949 | 127,376 | 126,658 | 126,953 | 126,405 | 126,111 | 125,502 | 125,687 | 125,356 | 125,026 | 124,217 | 124,425 | 124,068 | 123,630 | 119,962 | 122,559 | 131,237 | 116,199 | 111,794 | 119,191 | 107,887 | 104,484 | 103,615 | 107,880 | 102,336 | 94,740 | 91,568 | 90,899 | 90,168 | 80,507 | 79,426 | 79,617 | 79,413 | 78,650 | 77,542 | 78,145 | 77,448 | 76,068 | 60,526 | ||||||||||||||||||||||||||||
| deemed dividends on preferred stock | 8,248,000 | 947,000 | 1,003,000 | 911,000 | 912,000 | 929,000 | 894,000 | 12,491,000 | 1,840,000 | 1,840,000 | 1,840,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| amortization of preferred stock beneficial conversion feature | -8,248,000 | 1,824,000 | 1,853,000 | 1,780,000 | 1,739,000 | 1,710,000 | 1,672,000 | -4,517,000 | 3,727,000 | 3,727,000 | 3,727,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on sale of path logic | 1,058,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| clinical testing | 56,971,000 | 43,167,000 | 56,186,000 | 59,791,000 | 56,690,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gross margin | 27,196,000 | 27,257,000 | 27,345,000 | 28,605,000 | 27,173,000 | 12,228,000 | 11,171,000 | 10,813,000 | 9,544,000 | 8,709,000 | 7,246,000 | 7,144,000 | 3,865,000 | 4,074,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| clinical testing revenue | 41,668,500 | 55,739,000 | 56,316,000 | 54,622,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| pharma services & research revenue | 4,229,750 | 5,022,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| biopharma & research revenue | 6,813,000 | 5,082,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| operating expenses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest and other income – net | -155,750 | -239,000 | -189,000 | 1,665,000 | -218,000 | -253,000 | -187,250 | -231,000 | -232,000 | -209,250 | -291,000 | -288,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income taxes | -260,500 | -125,000 | -161,000 | -756,000 | 129,000 | 20,000 | 603,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income taxes | 5,000 | 15,000 | 5,000 | 79,000 | 51,000 | 27,000 | 106,000 | 29,000 | 17,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per share | -0.005 | 0 | 0 | -0.01 | -0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of shares outstanding – basic | 60,537 | 60,425 | 60,277 | 53,483 | 48,263 | 45,027,010 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of shares outstanding – diluted | 60,537 | 60,425 | 60,277 | 56,016 | 52,775 | 48,715,063 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest and other income - net | 195,000 | -179,000 | -131,500 | -186,000 | -181,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| - basic | 12,818 | -0.01 | 0.01 | 49,277 | 0.005 | 0.02 | 0.01 | 46,264 | 11,236 | -0.02 | 0.01 | -0.03 | -0.02 | -0.01 | 31,367,144 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| - diluted | 13,481.5 | -0.01 | 0.01 | 53,469 | 0.005 | 0.02 | 0.01 | 50,923 | 12,056.5 | -0.02 | 0.01 | -0.03 | -0.02 | -0.01 | 38,243,857 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted avg number of shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest income—net | -265,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest income - net | -285,000 | -258,000 | -182,000 | -159,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income before taxes | 44,500 | -975,000 | 551,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| – basic | 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| – diluted | 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income / (loss) from operations | 861,000 | -711,000 | -591,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| benefit for income taxes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest and other income — net | -136,250 | -185,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| — basic and diluted | -0.008 | 43,103,707 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| - basic and diluted | -0.01 | -0.02 | -0.02 | -0.03 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| — basic | -0.02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| — diluted | -0.02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other operating expenses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of shares outstanding – basic and fully diluted | 31,400,947 |
We provide you with 20 years income statements for NeoGenomics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of NeoGenomics stock. Explore the full financial landscape of NeoGenomics stock with our expertly curated income statements.
The information provided in this report about NeoGenomics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.